XML 24 R9.htm IDEA: XBRL DOCUMENT
v3.22.2.2

Spin-Off of Embecta Corp. | 12 Months Ended
--- | ---
Sep. 30, 2022
Discontinued Operations and Disposal Groups [Abstract] |
Spin-Off of Embecta Corp. | Spin-Off of Embecta Corp. On April 1, 2022, the Company completed the spin-off of its Diabetes Care business as a separate publicly traded company named Embecta Corp. (“Embecta”) through a distribution of Embecta’s publicly traded common stock (listed on NASDAQ under the ticker symbol “EMBC”) to BD’s shareholders of record as of the close of business on March 22, 2022 (the “record date”). The Company distributed one share of Embecta common stock for every five common shares of BD outstanding as of the record date and shareholders received cash in lieu of fractional shares of Embecta common stock. BD retained no ownership interest in Embecta subsequent to the spin-off. The distribution is expected to qualify and has been treated as tax-free to the Company and its shareholders for U.S. federal income tax purposes. Embecta’s distributions on March 31, 2022 to the Company in connection with the spin-off included the issuance of $200 million of senior unsecured notes to the Company and a cash distribution of approximately $1.266 billion. Additional disclosures regarding the various financing transactions entered into by Embecta and related to the spin-off are provided in Note 16. The Company and Embecta entered into various agreements to effect the spin-off and provide a framework for the relationship between the Company and Embecta after the spin-off. Such agreements include the separation and distribution agreement, as well as the following ongoing agreements: a cannula supply agreement, an intellectual property matters agreement, a transition services agreement, manufacturing and supply agreements, a lease agreement, a distribution agreement to support commercial operations, a logistics services agreement and other agreements including an employee matters agreement and a tax matters agreement. Under these agreements, the Company will continue to provide certain products and services to Embecta following the spin-off. The agreements do not provide the Company with the ability to influence the operating or financial policies of Embecta subsequent to the spin-off date. Amounts included in the Company’s consolidated statements of income during the fiscal year ended September 30, 2022 as a result of these agreements were immaterial. The historical results of the Diabetes Care business (previously included in BD’s Medical segment) that was contributed to Embecta in the spin-off, as well as interest expense related to indebtedness incurred by Embecta prior to the spin-off date, have been reflected as discontinued operations in the Company’s consolidated financial statements for all periods prior to the spin-off date of April 1, 2022. Details of Income from Discontinued Operations, Net of Tax are as follows:
Millions of dollars | 2022 |  | 2021 |  | 2020
Revenues | $ | 538 |  |  | $ | 1,117 |  |  | $ | 1,043 |
Cost of products sold | 143 |  |  | 320 |  |  | 264 |
Selling and administrative expense | 78 |  |  | 148 |  |  | 141 |
Research and development expense | 32 |  |  | 59 |  |  | 57 |
Acquisition-related integration and restructuring expense | — |  |  | 6 |  |  | 10 |
Other operating expense, net | 95 |  |  | 35 |  |  | — |
Total Operating Costs and Expenses | 348 |  |  | 569 |  |  | 472 |
Operating Income | 190 |  |  | 549 |  |  | 571 |
Interest expense | (4) |  |  | — |  |  | — |
Other income, net | — |  |  | 2 |  |  | — |
Income from Discontinued Operations Before Income Taxes | 186 |  |  | 550 |  |  | 571 |
Income tax provision | 42 |  |  | 62 |  |  | 50 |
Income from Discontinued Operations, Net of Tax | $ | 144 |  |  | $ | 488 |  |  | $ | 522 |
During the year ended September 30, 2022, the Company incurred $30 million of expense which included costs to execute the spin-off and other costs for related residual activities. These costs are recorded within Income from Discontinued Operations, Net of Tax for the year ended September 30, 2022. Separation costs incurred by the Company prior to the spin-off date, including those for consulting, legal, tax and other advisory services associated with the spin-off, were previously recorded within Other operating (expense) income, net and are now included as a component of Income from Discontinued Operations, Net of Tax. The Company’s Revenues and Cost of products sold from continuing operations were recast to reflect previously eliminated intercompany transactions that occurred between BD and Embecta and that resulted in a third party sale in the same period. The impacts of these transactions to Embecta are also reflected as a component of Income from Discontinued Operations, Net of Tax. The following amounts associated with the Diabetes Care business are classified as assets and liabilities of discontinued operations in the Company’s consolidated balance sheet at September 30, 2021:
Millions of dollars | 2021
Assets |
Trade receivables, net | $ | 147 |
Inventories | 123 |
Prepaid expenses and other | 23 |
Current Assets of Discontinued Operations | 293 |
Property, Plant and Equipment, Net | 390 |
Goodwill and Other Intangibles, Net | 27 |
Other Assets | 6 |
Noncurrent Assets of Discontinued Operations | $ | 423 |
Liabilities |
Accounts payable | $ | 54 |
Accrued expenses | 75 |
Salaries, wages and related items | 28 |
Current Liabilities of Discontinued Operations | 157 |
Deferred Income Taxes and Other Liabilities | 16 |
Noncurrent Liabilities of Discontinued Operations | $ | 17 |
The Company recorded its distribution of net liabilities to Embecta as an increase in Retained earnings. The amount recorded reflected the carrying amounts, as of April 1, 2022, of the net liabilities distributed and included $1.650 billion of debt issued by Embecta, as further discussed above and in Note 16, as well as $265 million of cash. The Company also recorded a net decrease to Accumulated other comprehensive loss of $251 million to derecognize foreign currency translation losses which were attributable to Embecta.

X
- References No definition available. + Details
Name: | us-gaap_DiscontinuedOperationsAndDisposalGroupsAbstract
Namespace Prefix: | us-gaap_
Data Type: | xbrli:stringItemType
Balance Type: | na
Period Type: | duration

X
- Definition The entire disclosure related to a disposal group. Includes, but is not limited to, a discontinued operation, disposal classified as held-for-sale or disposed of by means other than sale or disposal of an individually significant component. + References Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Publisher FASB -Name Accounting Standards Codification -Topic 360 -URI https://asc.fasb.org/topic&trid=2155823 Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Publisher FASB -Name Accounting Standards Codification -Topic 205 -SubTopic 20 -URI https://asc.fasb.org/subtopic&trid=2122178 + Details
Name: | us-gaap_DisposalGroupsIncludingDiscontinuedOperationsDisclosureTextBlock
Namespace Prefix: | us-gaap_
Data Type: | dtr-types:textBlockItemType
Balance Type: | na
Period Type: | duration